Before You Invest in Sopan Pharmaceuticals Limited IPO, Take a Closer Look at the Company
Thu, Apr 16, 2026 10:41 AM on Company Analysis, Latest,
Company Profile
Sopan Pharmaceuticals Limited (SOPL) is a Nepal based public limited company registered on 2066/05/05 BS under the Company Act 2063. The company's factory is located at Vishunudol, Lalitpur and its corporate office is at Tinkunne, Kathmandu. They can be reached at info@sopanpharma.com or through their website www.sopanpharma.com.
The company is in the business of manufacturing and selling allopathic medicines across Nepal. They started official production in early 2022 and began selling medicines in the market from late 2021. Their medicines are distributed across all major cities and rural areas of Nepal through a wide sales and distribution network covering 13 sales regions.
They currently hold manufacturing licenses for 116 medicines and are actively selling 78 medicines in the market. Their products cover four forms - tablets and capsules, syrups and suspensions, creams and ointments, and dry powder syrups. Some well-known product names include Cetopan, Myzith, Montrin, Ulshield, Cefmex, Alerz, and Pbin, covering common health conditions like infections, pain, allergy, digestion, and respiratory issues. The company is also WHO-GMP and ISO 9001:2015 certified, meaning their factory and processes meet international quality standards. Learn More
Board of Directors:
|
Name |
Position |
Age |
Qualification |
|
Dr. Anil Pokhrel |
Chairman (Founder Group, Representative of Sopan Multiple Company Ltd.) |
51 |
MD (Internal Medicine), DM (Nephrology) |
|
Mrs. Kriti Kumari Mahatho |
Director (Founder Group) |
43 |
Bachelor's (Management) |
|
Mr. Bhimlal Poudyal |
Director (Founder Group) |
61 |
Bachelor's (Management) |
|
Mr. Anis Shah |
Director (Founder Group, Representative of Sopan Multiple Company Ltd.) |
38 |
Master's (Management) |
|
Mr. Aang Dorji Lama |
Director (Founder Group, Representative of Sopan Multiple Company Ltd.) |
59 |
Master's (Construction Management) |
About the Issue & Rating
Sopan Pharmaceuticals is issuing 42,90,000 ordinary shares at Rs. 100 per share to the general public, raising a total of Rs. 42.90 Crore. The IPO is managed by NMB Capital Limited and investors should note that the company has received a "CARE-NP B (Is)" credit rating, which indicates High risk of default regarding timely servicing of financial obligations, and this should be carefully considered before investing.
|
Particulars |
Details |
|
Company Symbol |
SOPL |
|
Total Shares Issued |
42,90,000 shares |
|
Face Value per Share |
Rs. 100 |
|
Total Issue Size |
Rs. 42,90,00,000 (Rs. 42.90 Crore) |
|
Nepalese in Foreign Employment |
4,29,000 Units ( 10%) |
|
Employee |
1,71,600 Units (4%) |
|
Mutual Fund |
2.14,500 Units (5%) |
|
General Public |
34,74,900 |
|
Issue Open Date (General Public) |
2083/01/03 BS |
|
Issue Close Date (Early) |
2083/01/08 BS |
|
Issue Close Date (Undersubscribed) |
2083/01/17 BS |
Financial Ratio
Net Worth Per Share:
Net worth per share has been consistently growing from Rs. 44.41 in 2079/080 to Rs. 92.15 in 2081/082 - more than doubling in just three years. The projected figures show it crossing Rs. 100 and heading toward Rs. 126 by 2084/085. This is a positive sign as it means the company's overall value per share is increasing year by year. However, since the IPO price is Rs. 100, the current net worth per share of Rs. 92.85 is still slightly below the issue price, meaning investors are paying slightly more than what the company currently holds in value per share.
Earning Per Share:
This is the most important ratio for investors. The company was in heavy loss in its first two years, losing Rs. 42 per share in 2079/080. It then recovered to a profit of Rs. 18.33 in 2081/082, which was a great turnaround. However, the 2082 Poush unaudited EPS has dropped sharply to just Rs. 0.70, which is a concern and needs close attention. The company projects EPS to recover and grow to Rs. 13 by 2084/085, but at the IPO price of Rs. 100, the projected P/E ratio works out to around 10x, which is moderate but the near term earnings weakness is something investors must keep in mind.
Reserve and Surplus:
Reserves dropped in 2080/081 because the company was still in loss during its early years. But from 2081/082 onward, reserves jumped significantly as the company started making profit. This shows the company is now retaining and building its financial strength. The projected reserves nearly tripling by 2084/085 is encouraging, but investors should note these are company estimates and actual performance may vary.
Financial Highlight:
|
Actual |
Expected |
||||||
|
Particulars |
2079/080 |
2080/081 |
2081/082 |
2082 Poush (Unaudited) |
2082/083 |
2083/084 |
2084/085 |
|
Total Non-Current Assets (Rs. '000) |
1,678,816 |
1,678,859 |
1,625,018 |
1,616,954 |
1,685,059 |
1,774,030 |
1,798,331 |
|
Total Current Assests (Rs '000) |
166,047 |
290,959 |
699,540 |
773,520 |
1,083,516 |
1,203,838 |
1,471,301 |
|
Total Assets (Rs. '000) |
1,838,379 |
1,969,819 |
2,324,558 |
2,390,474 |
2,768,576 |
2,977,868 |
3,269,632 |
|
Total Equity (Rs. '000) |
879,854 |
1,090,881 |
1,616,023 |
1,625,075 |
2,190,786 |
2,380,915 |
2,603,923 |
|
Total Liability (Rs. '000) |
958,534 |
878,938 |
708,535 |
765,400 |
577,790 |
596,953 |
665,709 |
|
Total Liability & Equity (Rs. '000) |
1,838,379 |
1,969,819 |
2,324,558 |
2,390,474 |
2,768,576 |
2,977,868 |
3,269,632 |
|
Paid-up Capital (Rs. '000) |
6,80,000 |
9,90,000 |
12,87,000 |
12,87,000 |
17,16,000 |
17,16,000 |
17,16,000 |
|
Capital Advance (Rs. '000) |
16,300 |
- |
- |
- |
- |
- |
- |
|
Reserves & Funds (Rs. '000) |
1,83,545 |
1,00,881 |
3,29,023 |
3,38,075 |
4,74,786 |
6,64,915 |
8,87,923 |
|
Total Net Worth (Rs. '000)* |
3,01,963 |
5,12,999 |
11,85,970 |
11,95,022 |
17,60,733 |
19,50,862 |
21,73,870 |
|
No. of Shares ('000) |
6,800 |
9,900 |
12,870 |
12,870 |
17,160 |
17,160 |
17,160 |
|
Net Profit / (Loss) (Rs. '000) |
(2,86,525) |
-82,664 |
2,17,792 |
9,052 |
1,45,763 |
1,90,130 |
2,23,008 |
|
Return on Net Worth (%) |
-94.89% |
-16.11% |
19.89% |
0.76% |
9.46% |
9.75% |
10.26% |
|
Paid-up Capital Per Share (Rs.) |
100 |
100 |
100 |
100 |
100 |
100 |
100 |
Is Sopan Pharmaceuticals IPO Safe for Your Rs. 1,000 Investment?
The company issues it’s IPO in Par value of Rs. 100 but it’s current net worth per share is still below 100, The Net Worth Per share of the company as per offer letter is 92.85 for the fiscal year 2082/83 Poush end. It shows investor are still paying high price compare to the net worth per share of the company. However this is consider safe for the investment because the company projects it’s Net worth per share more than 126 in next 2 years.
The company earned Rs. 18.33 per share in 2081/082 but this crashed to just Rs. 0.70 in 2082 Poush. That is a massive drop and raises questions about whether the profits were sustainable. It shows the company is loosing money till it’s second quarter. Company expected it’s EPS to reach more than 13 in next two years that give investor confidence to invest in the share offered by the company.
Low Credit Rating The company received "CARE-NP B" rating, which officially means "High risk of default." This is given by an independent rating agency and is not something to ignore. Out of all ratings, B is towards the weaker end.
This is an educational analysis based on the offer document. It is not financial advice. Always consult a licensed investment advisor before investing.
